Cargando…

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers

PURPOSE: Patients with advanced/relapsed rare cancers have few treatment options. Analysis of circulating tumor DNA in plasma may identify actionable genomic biomarkers using a non-invasive approach. PATIENTS AND METHODS: Rare cancer patients underwent prospective plasma-based NGS testing. Tissue NG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuma, Hitomi Sumiyoshi, Yonemori, Kan, Kojima, Yuki, Tanioka, Maki, Sudo, Kazuki, Noguchi, Emi, Hijioka, Susumu, Wakakuwa, Keiko, Kato, Ken, Hirakawa, Akihiro, Kuchiba, Aya, Kubo, Takashi, Ichikawa, Hitoshi, Yoshida, Akihiko, Yatabe, Yasushi, Nakamura, Kenichi, Mano, Hiroyuki, Yamamoto, Noboru, Fujiwara, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652216/ https://www.ncbi.nlm.nih.gov/pubmed/34900683 http://dx.doi.org/10.3389/fonc.2021.732525

Ejemplares similares

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
por: Yazaki, Shu, et al.
Publicado: (2022)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping
por: Kojima, Yuki, et al.
Publicado: (2023)

Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma
por: Kojima, Yuki, et al.
Publicado: (2023)

Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
por: Yazaki, Shu, et al.
Publicado: (2022)

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy
por: Watanabe, Sho, et al.
Publicado: (2023)

Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Correction to: COVID arm that appeared in the contralateral upper extremity after mRNA‑1273 booster inoculation
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Changes in HER3 expression profiles between primary and recurrent gynecological cancers
por: Kojima, Yuki, et al.
Publicado: (2023)

Drug induced interstitial lung disease in oncology phase I trials
por: Yonemori, Kan, et al.
Publicado: (2016)

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial
por: Okuma, Hitomi S., et al.
Publicado: (2020)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
por: Kitadai, Rui, et al.
Publicado: (2021)

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system
por: Shimoi, Tatsunori, et al.
Publicado: (2018)

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials
por: Hirakawa, Akihiro, et al.
Publicado: (2017)

ACT-1 Multicenter investigator-initiated registration-directed Phase 2 study of E7090 in subjects with advanced or recurrent solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
por: Takahashi, Masamichi, et al.
Publicado: (2021)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
por: Chiba, Yohei, et al.
Publicado: (2022)

Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2023)

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project
por: Okuma, Hitomi S., et al.
Publicado: (2019)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
por: Kimbara, Shiro, et al.
Publicado: (2018)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
por: Iizumi, Sakura, et al.
Publicado: (2017)

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
por: Higashiyama, Ryoko Inaba, et al.
Publicado: (2022)

Rehabilitation Approach for a Child with Cerebral Palsy and Upper Limb Deficiency
por: Mano, Hiroshi, et al.
Publicado: (2021)

Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
por: Watase, Chikashi, et al.
Publicado: (2021)

Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
por: Omura, Takaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a9ijij6e971v3un864b41hnvud